Company Overview:
Exelixis
EXEL is a biotech leader in oncology, with its flagship drug cabozantinib generating $1.81B in U.S. revenue for FY 2024.
Key Catalysts:
Pipeline Strength & Upcoming Data Readouts 🔬
Zanzalintinib (XL092): Pivotal 2025 trial results could position it as a next-gen cancer therapy, driving potential upside.
Shareholder Value & Buyback Program 💰
A new $500M stock buyback, following the current $500M program, signals strong financial confidence.
With 22B in cash, Exelixis has flexibility for R&D, acquisitions, and expansion.
Revenue Growth & Market Positioning 📊
Cabozantinib continues to expand market share, securing its position in oncology treatments.
Investment Outlook:
Bullish Case: We are bullish on EXEL above $32.00-$33.00, driven by pipeline advancements, revenue growth, and capital strategy.
Upside Potential: Our price target is $48.00-$50.00, supported by key trial results, buybacks, and a strong cash position.
🚀 Exelixis—Advancing Cancer Treatments & Delivering Shareholder Value. #EXEL #BiotechStocks #OncologyInnovation
Exelixis
EXEL is a biotech leader in oncology, with its flagship drug cabozantinib generating $1.81B in U.S. revenue for FY 2024.Key Catalysts:
Pipeline Strength & Upcoming Data Readouts 🔬
Zanzalintinib (XL092): Pivotal 2025 trial results could position it as a next-gen cancer therapy, driving potential upside.
Shareholder Value & Buyback Program 💰
A new $500M stock buyback, following the current $500M program, signals strong financial confidence.
With 22B in cash, Exelixis has flexibility for R&D, acquisitions, and expansion.
Revenue Growth & Market Positioning 📊
Cabozantinib continues to expand market share, securing its position in oncology treatments.
Investment Outlook:
Bullish Case: We are bullish on EXEL above $32.00-$33.00, driven by pipeline advancements, revenue growth, and capital strategy.
Upside Potential: Our price target is $48.00-$50.00, supported by key trial results, buybacks, and a strong cash position.
🚀 Exelixis—Advancing Cancer Treatments & Delivering Shareholder Value. #EXEL #BiotechStocks #OncologyInnovation
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.